Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [9648]

Global disparities in cancer care for conflict-affected populations: Africa's...

Prof Nazik Hammad - University of Toronto, Toronto, Canada

Global disparities in cancer care for conflict-affected populations: Africa's neglected crisis ( Prof Nazik Hammad - University of Toronto, Toronto, Canada )

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in...

Dr Rahul Aggarwal - University of California, San Francisco, USA

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC ( Dr Rahul Aggarwal - University of California, San Francisco, USA )

The evolving treatment landscape in immune thrombocytopenia

Dr Hanny Al-Samkari - Massachusetts General Hospital, Boston, USA

The evolving treatment landscape in immune thrombocytopenia ( Dr Hanny Al-Samkari - Massachusetts General Hospital, Boston, USA )

Highlights from APCCC 2026

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires...

Highlights from APCCC 2026 ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

ASCO 2026: Updates in bladder cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires...

ASCO 2026: Updates in bladder cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

ASCO 2026: Updates in renal cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires...

ASCO 2026: Updates in renal cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires...

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

First-in-class switchable allogeneic CAR-T therapy shows promising activity in...

Prof Martin Wermke - National Center for Tumor Diseases, Dresden, Germany

$First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML ( Prof Martin Wermke - National Center for Tumor Diseases, Dresden, Germany )$

Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular...

Dr Benoit Tessoulin - CHU de Nantes, Nantes, France

Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups ( Dr Benoit Tessoulin - CHU de Nantes, Nantes, France )

Epcoritamab improves progression-free survival in relapsed or refractory large...

Prof Christopher Fox - University of Nottingham, Nottingham, UK

$Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma ( Prof Christopher Fox - University of Nottingham, Nottingham, UK )$

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1...

Dr Chiara Sartor - University of Bologna, Bologna, Italy

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure ( Dr Chiara Sartor - University of Bologna, Bologna, Italy )

More from ecancer